Vietnam Companion Diagnostics Market

Vietnam Companion Diagnostics Market Overview:

The Vietnam companion diagnostics market size reached USD 45.29 Million in 2024. The market is projected to reach USD 125.39 Million by 2033, exhibiting a growth rate (CAGR) of 10.72% during 2025-2033. The market is driven by the rapid adoption of liquid biopsy and non-invasive diagnostic technologies, accelerated growth in personalized medicine and NGS-based companion diagnostics, and significant government healthcare infrastructure investment and digital health expansion. Additionally, the increasing focus on precision medicine and targeted therapies is expanding the Vietnam companion diagnostics market share.

Vietnam Companion Diagnostics Market Trends:

Speedy Adoption of Non-Invasive Diagnostic Technologies

Vietnamese healthcare is experiencing unprecedented growth in liquid biopsy and non-invasive diagnostic technology adoption, revolutionizing cancer detection and monitoring strategies. Vietnamese healthcare providers are increasingly adopting liquid biopsy solutions based on their better patient compliance rates and lesser procedural risks relative to conventional tissue biopsies. The need for liquid biopsy is rising as a result of the technology being non-invasive and providing enhanced diagnostic accuracy. This technological advancement is especially relevant in Vietnam's urban healthcare facilities, where sophisticated diagnostic capacity is being increasingly applied to address increasing demand from the country's expanding middle-class population. The fusion of liquid biopsy platforms allows for real-time evaluation of response to treatment and disease progression, facilitating more informed therapeutic decision-making. Vietnamese healthcare facilities are progressively aware that non-invasive diagnostics not only enhance the patient experience but also decrease healthcare system burden by providing earlier intervention and more targeted treatment choice.

Rapid Expansion in Personalized Medicine Adoption

Vietnam's healthcare environment is undergoing a dramatic change through rapid adoption of personalized medicine and next-generation sequencing-based companion diagnostics. Medical institutions throughout the country are strategically investing in NGS technology platforms to support targeted therapy selection and improve patient outcomes in oncology care. Comprehensive genomic profiling is widely being employed by Vietnamese diagnostic laboratories and hospitals to detect actionable mutations and inform cancer treatment, thereby impelling the Vietnam companion diagnostics market. The market for companion diagnostics is driven by collaborations between foreign diagnostic firms and local healthcare providers, enabling technology transfer and clinical skills creation. This strategy of personalized medicine is especially important to Vietnam's healthcare environment, where targeted treatment selection can optimize therapeutic response with minimal healthcare expenses. The increasingly available targeted therapies in the Vietnamese marketplace further underscores the paramount significance of companion diagnostic testing for best-in-class patient management and enhanced clinical outcomes.

Strategic Government Healthcare Infrastructure Investment and Digitalization

The Vietnamese government's strategic investment in healthcare infrastructure development and digital health expansion is driving significant opportunities for next-generation diagnostic technologies, including companion diagnostics integration across the healthcare continuum. Government programs are actively encouraging modernization of diagnostic capacity and development of integrated healthcare networks facilitating precision medicine strategies. The digital transformation plans of the Ministry of Health cover the use of electronic health records, intelligent hospital systems, and telemedicine platforms for enhanced availability of companion diagnostic services in urban and rural areas. Genomic medicine capacities and precision diagnostics are being targeted by Vietnamese healthcare policymakers as the major elements of the country's national healthcare modernization initiative. These state investments are creating the regulatory environment and the technological support required for widespread companion diagnostic adoption, while at the same time funding workforce development initiatives to educate healthcare providers in molecular diagnostics interpretation and clinical application.

Vietnam Companion Diagnostics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on product and service, technology, indication, and end user.

Product and Service Insights:

• Assays, Kits and Reagents
• Software and Services

The report has provided a detailed breakup and analysis of the market based on product and service. This includes assays, kits and reagents and software and services.

Technology Insights:

• Immunohistochemistry (IHC)
• Polymerase Chain Reaction (PCR)
• In-situ Hybridization (ISH)
• Real-time PCR (RT-PCR)
• Gene Sequencing
• Others

A detailed breakup and analysis of the market based on technology have also been provided in the report. This includes immunohistochemistry (IHC), polymerase chain reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), gene sequencing, and others.

Indication Insights:

• Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Melanoma
  • Others
• Neurological Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Others

The report has provided a detailed breakup and analysis of the market based on indication. This includes cancer (lung cancer, breast cancer, colorectal cancer, gastric cancer, melanoma, and others), neurological diseases, infectious diseases, cardiovascular diseases, and others.

End User Insights:

• Pharmaceutical and Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations
• Others

A detailed breakup and analysis of the market based on end user have also been provided in the report. This includes pharmaceutical and biopharmaceutical companies, reference laboratories, contract research organizations, and others.

Regional Insights:

• Northern Vietnam
• Central Vietnam
• Southern Vietnam

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Vietnam, Central Vietnam, and Southern Vietnam.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Vietnam Companion Diagnostics Market News:

• September 2025: Molbio Diagnostics, a company specializing in point-of-care (POC) diagnostics, and UE LifeSciences, a health tech innovator from Philadelphia dedicated to early cancer detection, have revealed a unique partnership aimed at enhancing access to early breast cancer detection in over 50 countries in the developing world. In this partnership, Molbio will distribute UE LifeSciences' iBreastExam, a painless, radiation-free screening device cleared by the US Food and Drug Administration (FDA), throughout India, Africa, the Middle East, CIS nations, the Philippines, Indonesia, and Vietnam. The goal is to tackle the issue of late diagnosis, which continues to be a primary factor in avoidable breast cancer deaths.

Vietnam Companion Diagnostics Market Report Coverage:

Key Questions Answered in This Report:

• How has the Vietnam companion diagnostics market performed so far and how will it perform in the coming years?
• What is the breakup of the Vietnam companion diagnostics market on the basis of product and service?
• What is the breakup of the Vietnam companion diagnostics market on the basis of technology?
• What is the breakup of the Vietnam companion diagnostics market on the basis of indication?
• What is the breakup of the Vietnam companion diagnostics market on the basis of end user?
• What is the breakup of the Vietnam companion diagnostics market on the basis of region?
• What are the various stages in the value chain of the Vietnam companion diagnostics market?
• What are the key driving factors and challenges in the Vietnam companion diagnostics market?
• What is the structure of the Vietnam companion diagnostics market and who are the key players?
• What is the degree of competition in the Vietnam companion diagnostics market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Vietnam companion diagnostics market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Vietnam companion diagnostics market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Vietnam companion diagnostics industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.